(S)-2-(cyclobutylamino)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)isonicotinamide dihydrochloride

Catalog No. :
ACRLMM252
CAS No. :
2320953-89-5
Molecular Formula :
C22H30Cl2N4O2
Molecular Weight :
453.41

IUPAC Name:(S)-2-(cyclobutylamino)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)isonicotinamide dihydrochloride

(S)-2-(cyclobutylamino)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)isonicotinamide dihydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(S)-2-(cyclobutylamino)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)isonicotinamide dihydrochloride
IUPAC Name(S)-2-(cyclobutylamino)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)isonicotinamide dihydrochloride
Molecular FormulaC22H30Cl2N4O2
Molecular Weight453.41
SMILESCl.Cl.O=C(NC[C@H](O)CN1CCC2=CC=CC=C2C1)C1=CC(NC2CCC2)=NC=C1
InChI KeyCDKUMVXFXBTOBE-FJSYBICCSA-N
SynonymEPZ015866, GSK 3203591 | 2-(Cyclobutylamino)-N-[(2S)-3-(3,4-dihydro-2(1H)-isoquinolinyl)-2-hydropropyl]-4-pyridinecarboxamide dihydrochloride
CAS No.2320953-89-5
PubChem CID124201849

Synthetic Route by SureRoute

1. ACRLMM252 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACOAMY269 route compound structure diagram
    ACOAMY2691858273-09-2 In Stock
  2. Plus
  3. ACCKYR365 route compound structure diagram
    ACCKYR3651251225-65-6 In Stock
  4. Then
  5. ACRLMM252 route product structure diagram
    ACRLMM2522320953-89-5
Inquiry

2. ACRLMM252 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACOAMY269 route compound structure diagram
    ACOAMY2691858273-09-2 In Stock
  4. Then
  5. ACRLMM252 route product structure diagram
    ACRLMM2522320953-89-5
Inquiry

Comments (0)